Restricted accessResearch articleFirst published online 2016-4-26
Strong Impact of Chronic Cerebral Hypoperfusion on Neurovascular Unit,Cerebrovascular Remodeling,and Neurovascular Trophic Coupling in Alzheimer’s Disease Model Mouse
Although chronic cerebral hypoperfusion (CCH) may affect Alzheimer’s disease (AD)
pathogenesis, the mechanism remains elusive. In the present study, we investigated the
role of CCH on an AD mouse model in neurovascular unit, cerebrovascular remodeling, and
neurovascular trophic coupling. Moreover, examined protective effect of galantamine.
Alzheimer’s disease transgenic mice (APP23) were subjected to bilateral common carotid
arteries stenosis with ameroid constrictors for slowly progressive cerebral hypoperfusion.
CCH exacerbated neuronal loss and decrease of α7 subunit of nicotinic
acetylcholine receptors (α7-nAChRs) expression in hippocampus and
thalamus at 12 months. Meanwhile, CCH greatly induced advanced glycation end products
expression, and blood-brain barrier leakage through observing IgG and MMP9 expressions.
Furthermore, a significant number of dramatic enlarged cerebral vessels with remodeling,
BDNF/TrkB decreased in neurovascular trophic coupling. The present study demonstrated that
CCH strongly enhanced primary AD pathology including neurodegeneration, neurovascular unit
disruption, cerebrovascular remodeling and neurovascular trophic coupling damage in AD
mice, and that galantamine treatment greatly ameliorated such neuropathologic
abnormalities.
HishikawaN, FukuiY,
SatoK, KonoS,
YamashitaT, OhtaY,
DeguchiK, AbeK
(2015) Characteristic features of cognitive, affective and
daily living functions of late-elderly dementia. Geriatr
Gerontol Int, doi: 10.1111/ggi.12492[Epub ahead of print].
2.
WhitehousePJ,
PriceDL, ClarkAW, CoyleJT, DeLongMR
(1981) Alzheimer disease: Evidence for selective loss of
cholinergic neurons in the nucleus basalis. Ann Neurol10, 122–126.
3.
WeversA, WitterB, MoserN,
BurghausL, BanerjeeC, SteinleinOK, SchutzU, de
VosRA, SteurEN, LindstromJ, SchroderH
(2000) Classical Alzheimer features and cholinergic
dysfunction: Towards a unifying hypothesis?. Acta Neurol
Scand176 (Suppl),
42–48.
4.
GirouardH, IadecolaC
(2006) Neurovascular coupling in the normal brain and in
hypertension, stroke, and Alzheimer disease. J Appl Physiol
(1985)100, 328–335.
5.
JellingerKA, Mitter-FerstlE
(2003) The impact of cerebrovascular lesions in Alzheimer
disease–a comparative autopsy study. J Neurol250, 1050–1055.
6.
BellRD, ZlokovicBV
(2009) Neurovascular mechanisms and blood-brain barrier
disorder in Alzheimer’s disease. Acta Neuropathol118, 103–113.
7.
LourencoCF, LedoA,
DiasC, BarbosaRM, LaranjinhaJ
(2015) Neurovascular and neurometabolic derailment in aging
and Alzheimer’s disease. Front Aging Neurosci7, 103.
8.
ZlokovicBV
(2011) Neurovascular pathways to neurodegeneration in
Alzheimer’s disease and other disorders. Nat Rev
Neurosci12, 723–738.
9.
RuitenbergA, den
HeijerT, BakkerSL, van
SwietenJC, KoudstaalPJ, HofmanA, BretelerMM
(2005) Cerebral hypoperfusion and clinical onset of
dementia: The Rotterdam Study. Ann Neurol57, 789–794.
10.
KoriyamaY, FurukawaA, MuramatsuM, TakinoJ, TakeuchiM
(2015) Glyceraldehyde caused Alzheimer’s disease-like
alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma
cells. Sci Rep5, 13313.
11.
SasakiN, FukatsuR, TsuzukiK, HayashiY, YoshidaT, FujiiN,
KoikeT, WakayamaI, YanagiharaR, GarrutoR, AmanoN,
MakitaZ (1998)
Advanced glycation end products in Alzheimer’s disease and other
neurodegenerative diseases. Am J Pathol153, 1149–1155.
12.
SamochockiM, HoffleA, FehrenbacherA, JostockR, LudwigJ, ChristnerC, RadinaM, ZerlinM, UllmerC, PereiraEF, LubbertH, AlbuquerqueEX, MaelickeA
(2003) Galantamine is an allosterically potentiating ligand
of neuronal nicotinic but not of muscarinic acetylcholine receptors.
J Pharmacol Exp Ther305, 1024–1036.
TokuchiR, HishikawaN, MatsuzonoK, TakaoY,
WakutaniY, SatoK,
KonoS, OhtaY,
DeguchiK, YamashitaT, AbeK
(2015) Cognitive and affective benefits of combination
therapy with galantamine plus cognitive rehabilitation for Alzheimer’s
disease. Geriatr Gerontol Int, doi: 10.1111/ggi.12488[Epub ahead of print].
17.
BoresGM, HugerFP, PetkoW,
MutlibAE, CamachoF, RushDK,
SelkDE, WolfV,
KosleyRWjr,
DavisL, VargasHM
(1996) Pharmacological evaluation of novel Alzheimer’s disease
therapeutics: Acetylcholinesterase inhibitors related to galanthamine.
J Pharmacol Exp Ther277, 728–738.
18.
Sturchler-PierratC,
AbramowskiD, DukeM,
WiederholdKH,
MistlC, RothacherS, LedermannB, BurkiK,
FreyP, PaganettiPA, WaridelC, CalhounME, JuckerM, ProbstA, StaufenbielM, SommerB
(1997) Two amyloid precursor protein transgenic mouse models
with Alzheimer disease-like pathology. Proc Natl Acad Sci U S
A94, 13287–13292.
19.
Sturchler-PierratC,
StaufenbielM
(2000) Pathogenic mechanisms of Alzheimer’s disease analyzed
in the APP23 transgenic mouse model. Ann N Y Acad Sci920, 134–139.
20.
VloeberghsE, Van
DamD, EngelborghsS, NagelsG, StaufenbielM, De
DeynPP (2004)
Altered circadian locomotor activity in APP23 mice: A model for BPSD
disturbances. Eur J Neurosci20, 2757–2766.
21.
Van
DamD, AbramowskiD, StaufenbielM, De
DeynPP (2005)
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine
on cognitive deficits in the APP23 model. Psychopharmacology
(Berl)180, 177–190.
22.
WinklerDT, BondolfiL, HerzigMC, JannL,
CalhounME, WiederholdKH, TolnayM, StaufenbielM, JuckerM
(2001) Spontaneous hemorrhagic stroke in a mouse model of
cerebral amyloid angiopathy. J Neurosci21, 1619–1627.
23.
AugustinHG, BraunK,
TelemenakisI,
ModlichU, KuhnW
(1995) Ovarian angiogenesis. Phenotypic characterization of
endothelial cells in a physiological model of blood vessel growth and
regression. Am J Pathol147, 339–351.
24.
KitamuraA, FujitaY, OishiN,
KalariaRN, WashidaK, MakiT,
OkamotoY, HaseY,
YamadaM, TakahashiJ, ItoH,
TomimotoH, FukuyamaH, TakahashiR, IharaM
(2012) Selective white matter abnormalities in a novel rat
model of vascular dementia. Neurobiol Aging33, 1012. e25–35.
25.
HeXL, WangYH,
BiMG, DuGH
(2012) Chrysin improves cognitive deficits and brain damage
induced by chronic cerebral hypoperfusion in rats. Eur J
Pharmacol680, 41–48.
FarkasE, LuitenPG, BariF
(2007) Permanent, bilateral common carotid artery occlusion
in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative
diseases. Brain Res Rev54, 162–180.
28.
AdibhatlaRM, HatcherJF
(2008) Phospholipase A(2), reactive oxygen species, and
lipid peroxidation in CNS pathologies. BMB Rep41, 560–567.
29.
UrabeT (2012)
[Molecular mechanism and new protective strategy for ischemic white
matter damages]. Rinsho Shinkeigaku52, 908–910.
30.
BangJ, JeonWK,
LeeIS, HanJS,
KimBY (2013)
Biphasic functional regulation in hippocampus of rat with chronic
cerebral hypoperfusion induced by permanent occlusion of bilateral common carotid
artery. PLoS One8, e70093.
31.
ZhaoY, GuJH,
DaiCL, LiuQ,
IqbalK, LiuF,
GongCX (2014)
Chronic cerebral hypoperfusion causes decrease of O-GlcNAcylation,
hyperphosphorylation of tau and behavioral deficits in mice.
Front Aging Neurosci6, 10.
32.
McKayBE, PlaczekAN, DaniJA
(2007) Regulation of synaptic transmission and plasticity by
neuronal nicotinic acetylcholine receptors. Biochem
Pharmacol74, 1120–1133.
33.
LiuQ, XieXT,
LukasRJ, St
JohnPA, WuJ
(2013) A novel nicotinic mechanism underlies
beta-amyloid-induced neuronal hyperexcitation. J
Neurosci33, 7253–7263.
NiRQ, MarutleA, NordbergA
(2013) Modulation of alpha 7 nicotinic acetylcholine
receptor and fibrillar amyloid-beta interactions in Alzheimer’s disease
brain. J Alzheimers Dis33, 841–851.
36.
Sims-RobinsonC,
KimB, RoskoA,
FeldmanEL
(2010) How does diabetes accelerate Alzheimer disease
pathology?. Nat Rev Neurol6, 551–559.
37.
YarchoanM, ArnoldSE
(2014) Repurposing diabetes drugs for brain insulin resistance
in Alzheimer disease. Diabetes63, 2253–2261.
38.
PerroneL, GrantWB
(2015) Observational and ecological studies of dietary
advanced glycation end products in national diets and Alzheimer’s disease incidence and
prevalence. J Alzheimers Dis45, 965–979.
39.
ZlokovicBV
(2008) The blood-brain barrier in health and chronic
neurodegenerative disorders. Neuron57, 178–201.
40.
SweeneyMD, SagareAP, ZlokovicBV
(2015) Cerebrospinal fluid biomarkers of neurovascular
dysfunction in mild dementia and Alzheimer’s disease. J Cereb
Blood Flow Metab35, 1055–1068.
41.
Arbel-OrnathM,
HudryE, Eikermann-HaerterK,
HouS, GregoryJL, ZhaoLZ,
BetenskyRA, FroschMP, GreenbergSM, BacskaiBJ
(2013) Interstitial fluid drainage is impaired in ischemic
stroke and Alzheimer’s disease mouse models. Acta
Neuropathol126, 353–364.
ThalDR, Capetillo-ZarateE,
LarionovS, StaufenbielM, ZurbrueggS, BeckmannN
(2009) Capillary cerebral amyloid angiopathy is associated
with vessel occlusion and cerebral blood flow disturbances.
Neurobiol Aging30, 1936–1948.
44.
ZekryD, DuyckaertsC, BelminJ, GeoffreC, MouliasR, HauwJJ
(2003) Cerebral amyloid angiopathy in the elderly: Vessel
walls changes and relationship with dementia. Acta
Neuropathol106, 367–373.
45.
FaracoG, IadecolaC
(2013) Hypertension: A harbinger of stroke and
dementia. Hypertension62, 810–817.
46.
Martinez-LemusLA,
HillMA, MeiningerGA
(2009) The plastic nature of the vascular wall: A continuum
of remodeling events contributing to control of arteriolar diameter and
structure. Physiology (Bethesda)24, 45–57.
47.
DeaneR, Du
YanS, SubmamaryanRK,
LaRueB, JovanovicS, HoggE,
WelchD, MannessL, LinC,
YuJ, ZhuH,
GhisoJ, FrangioneB, SternA,
SchmidtAM, ArmstrongDL, ArnoldB, LiliensiekB, NawrothP, HofmanF, KindyM,
SternD, ZlokovicB
(2003) RAGE mediates amyloid-beta peptide transport across
the blood-brain barrier and accumulation in brain. Nat
Med9, 907–913.
48.
NavaratnaD, FanX,
LeungW, LokJ,
GuoS, XingC,
WangX, LoEH
(2013) Cerebrovascular degradation of TRKB by MMP9 in the
diabetic brain. J Clin Invest123, 3373–3377.
